In support of this idea, it has already been shown that antitumor immunity in cancer patients is enhanced by the elimination of Tregs [43] and an over-abundance of tissue CD4 Tregs leads to additional dysfunctions in antigen-specific CD8 T cell responses [44]. The gene discussed is CD8A; the disease is cancer.